Immunodominant Glycoprotein 41 Epitope Identified by Seroreactivity in HIV Type 1-Infected Individuals
- 20 May 1996
- journal article
- research article
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 12 (8) , 705-713
- https://doi.org/10.1089/aid.1996.12.705
Abstract
A highly conserved gp41 epitope (amino acid sequence ELDKWA) has been described to elicit antibodies neutralizing a broad variety of HIV-1 strains. We analyzed the antibody reactivity of HIV-1-infected individuals from Argentina and Sweden to overlapping synthetic peptides covering aa 647–684 of HIV-1 MN gp41. An immunodominant antigenic determinant was discovered in the C-terminal region adjacent to the ELDKWA sequence. Most of the sera from both Argentina and Sweden reacted only with peptides representing this region. Two other patterns of reactivity were also observed: some sera reacted only with peptides spanning the central region of gp41, including the ELDKWA sequence; other sera reacted with both the central and C-terminal regions. Differences in reactivity were noted between Argentinian and Swedish sera in terms of peptides covering the central region. In addition, to determine the amino acids essential for antibody binding, seroreactivity against a set of substitution peptides covering the immunodominant epitope was studied. Results obtained indicated that carboxyl amino acids WNWFDI close to the ELDKWA sequence were the most important for antibody binding. Ability of sera, tested for peptide reactivity, to neutralize HIV-1 was also analyzed. High antibody reactivity to the central region was frequently found in sera with high neutralizing titers. This observation was not seen when seroreactivity to peptides spanning the C-terminal region was analyzed. These results suggest that the immunodominant epitope C terminal to the ELDKWA sequence is not involved in inducing neutralizing antibodies.Keywords
This publication has 36 references indexed in Scilit:
- Multifaceted Consequences of Anti-gp41 Monoclonal Antibody 2F5 Binding to HIV Type 1 VirionsAIDS Research and Human Retroviruses, 1995
- Generation of Human Monoclonal Antibodies against HIV-1 Proteins; Electrofusion and Epstein-Barr Virus Transformation for Peripheral Blood Lymphocyte ImmortalizationAIDS Research and Human Retroviruses, 1994
- A human monoclonal antibody against the CD4-binding site of HIV1 gp120 exhibits potent, broadly neutralizing activityResearch in Virology, 1991
- Rapid “tea-bag” peptide synthesis using 9-fluorenylmethoxycarbonyl (Fmoc) protected amino acids applied for antigenic mapping of viral proteinsImmunology Letters, 1991
- Neutralizing cross-reactive and non-neutralizing monoclonal antibodies to HIV-1 gp 120AIDS, 1990
- Conserved Sequence and Structural Elements in the HIV-1 Principal Neutralizing DeterminantScience, 1990
- Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous seraAIDS, 1990
- Human immunodeficiency virus type 1 p24 production and antigenic variation in tissue culture of isolates with various growth characteristicsJournal of Medical Virology, 1989
- Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.Proceedings of the National Academy of Sciences, 1988
- Neutralization of the AIDS Retrovirus by Antibodies to a Recombinant Envelope GlycoproteinScience, 1986